FLT3 and acute myeloid leukemia: In this trial, children with FLT3-ITD AML are non-randomly assigned to treatment with sorafenib in combination with standard chemotherapy for assessment of feasibility (stage 1) and efficacy (stage 2), then taken to HSCT with the best available donor.